Secondary Myeloid Malignancy after Treatment of Acute Lymphoblastic Leukemia (ALL)

Published: June 16, 2009
Abstract Views: 162
PDF: 177
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Treatment of childhood acute lymphoblastic leukemia (ALL) has made tremendous strides over the past 20 years, but has been complicated by the induction of secondary tumors after some regimens. The cumulative incidence of therapy-related myeloid leukemia and myelodysplastic syndrome (referred to collectively as t-ML) varies widely among treatment protocols, from 1% to 12%.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Relling, M. V. (2009). Secondary Myeloid Malignancy after Treatment of Acute Lymphoblastic Leukemia (ALL). Hematology Meeting Reports (formerly Haematologica Reports), 2(15). https://doi.org/10.4081/hmr.v2i15.607